This site is part of the Informa Connect Division of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC's registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 3099067.

TIDES Europe: Oligonucleotide and Peptide Therapeutics
12 - 14 Nov 2024
Hamburg Congress CentreHamburg, Germany

Thomas Frischmuth
Managing Director at baseclick GmbH


Since more than 30 years Thomas Frischmuth is actively working in the life science field as researcher (university as well as industry, more than 70 publications and several patents), advisor and consultant (companies and public organization) and in management position.

The research activities ranges from chemical synthesis (small scale and large scale), chemical analyses, molecular and cell biology, biotech synthesis (small and large scale), diagnostic, medical device (heart support systems), agriculture and drug to treatment development.

Thomas developed and evaluated 6 drugs and vaccines pre-clinically and brought 4 of them into clinical evaluation studies. One drug is marketed for cancer treatment.

In 2003, Thomas founded his own private venture fund company (Gradus Venture GmbH) and since then has co-founded and invested of today in 6 companies.

Agenda Sessions

  • Development of Targeted Oligonucleotide Therapy for Respiratory Diseases